The US Food and Drug Administration has granted approval to Bristol-Myers Squibb’s drug Cobenfy® (xanomeline and trospium ...

The US Food and Drug Administration has approved the new drug Cobenfy, which is owned by pharmaceutical firm Bristol Myers ...

Bristol Myers Squibb stock jumped after the pharma company won approval for its new schizophrenia drug late Thursday. “This ...

The Bristol Myers Squibb medicine is said relieve symptoms without causing some of the harsh side effects of drugs already in use. Meanwhile, thousands of patients allege in a lawsuit that drugs used ...

Data through the week points to a still-resilient economy overall, leaving traders uncertain about the Fed’s next move.

Stock futures were modestly higher ahead of the release of the Federal Reserve's preferred measures of inflation, as major ...

KarXT — now with the brand name Cobenfy— is expected to be available in October with a list price of about $22,500 annually. The drug represents a new way to treat adults with schizophrenia.

The first new type of medication in decades to help fight against schizophrenia was approved on Thursday by the U.S. Food and ...

Bristol Myers Squibb's Cobenfy has been approved by the FDA as the first new treatment for schizophrenia in decades. The ...

As of now, Bristol Myers Squibb has registered a Year-to-Date (YTD) stock performance of +1.48%. This figure starkly contrasts with the S&P 500’s impressive YTD performance of +20.45%. While BMY’s ...

With U.S. stock markets set to open in two hours, Bristol Myers Squibb Co. (BMY) was up 4.6% in pre-market trading, and Las Vegas Sands Corp. (LVS) was up 4.4%. Back To Top ...

Inflation moderating towards the central bank's 2% target gave the Fed enough room to commence its policy easing cycle with a 50 basis point rate cut last week.